NF Clinical Trials

More information is available on the NF Clinical Trial Fact Sheet.

 

Neurofibromatosis1 Clinical Trials  (Updated February 2012)

General NF1 Clinical Trials

• Study of Disease Severity in Adults with Neurofibromatosis Type 1 (NF1)
• Natural History Study of Patients with Neurofibromatosis Type 1
• Neurofibromatosis Type 1 Patient Registry
• Neurofibromatosis type 1 Genome Project

Cutaneous Neurofibroma Trials

• Topical Rapamycin Therapy to Alleviate Cutaneous Neurofibromas of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis 1 (NF1)
  
• Pilot Study of Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults with Neurofibromatosis 1
• Ranibizumab for Neurofibromas Associated with Neurofibromatosis 1
• First clinical Study of Erbium-Yttrium Aluminum Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas

Plexiform Neurofibroma Trials

• Combination Chemotherapy in Treating Patients with Neurofibromatosis and Progressive Plexiform Neurofibromas
• Study of Pegintron for Plexiform Neurofibromas
• A Phase II Study of AZD2171 in Adult Patients with Neurofibromatosis Type 1 and Extensive Plexiform and Paraspinal Neurofibromas
• Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas
  
• Sirolimus to Treat Plexiform Neurofibromas in Patients with Neurofibromatosis Type 1
• Study of Tasigna/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients with Plexiform Neurofibromas
• Pegintron to Treat Plexiform Neurofibromas in Children and Young Adults
• AZD6244 Hydrogen Sulfate for Children with Nervous System Tumors
• A Pilot Study of Sutent®/Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor in Subjects With NF-1 Plexiform Neurofibromas

Learning Disabilities / Attention Deficit Trials

• Trial to Evaluate the Safety of Lovastatin in Individuals with Neurofibromatosis Type 1 (NF1)
  
• A Randomized Placebo-Controlled Study of Lovastatin in Children with NF1
• Neurobiology and Treatment of Reading Disability in Neurofibromatosis Type 1 (NF1)
• Analysis of Stored Data Collected From Individuals Administered Neurobehavioral Assessments on IRB-Approved Protocols

Bone Problem Trials

• Multicenter Study of Tibial Dysplasia in Neurofibromatosis Type 1 (NF1) Patients
• Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With Neurofibromatosis Type 1

Malignant Peripheral Nerve Sheath Tumor (MPNST) Trials

• Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

Brain Tumor (Glioma) Trials

• Tarceva/Rapamycin for Children with Low-Grade Gliomas With and Without Neurofibromatosis Type 1 (NF1)
• Phase II Study of Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas
• A Phase II Study of RAD001 (Everolimus) for Children With NeurF1 and Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas

 

Neurofibromatosis 2 Clinical Trials

General NF2 Trials

• A Prospective Natural History Study of Patients With Neurofibromatosis Type 2 (NF2)

Schwannoma Trials

• Bevacizumab for Symptomatic Vestibular Schwannomas in Neurofibromatosis Type 2 (NF2)
• Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
• A Single Arm, Monocenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 – Related Vestibular Schwannoma
• Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinib in Vivo in Vestibular Schwannomas

Meningioma Trials

• Phase II Trial of Sunitinib (SU011248) in Patients with Recurrent or Inoperable Meningioma 
• Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas
• Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2